Detalhe da pesquisa
1.
Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
Blood
; 127(9): 1128-37, 2016 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26675347
2.
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Br J Haematol
; 162(5): 657-69, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23826755
3.
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
Anticancer Drugs
; 24(10): 1030-8, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23995855